Earnings Feed
Start Free
Home/Filings/4/0001802768-25-000105
4//SEC Filing

Legorreta Pablo G. 4

Accession 0001802768-25-000105

CIK 0001802768other
View on SEC.govCompany Profile

Filed

Aug 7, 8:00 PM ET

Accepted

Aug 8, 5:00 PM ET

Size

19.9 KB

Accession

0001802768-25-000105

Insider Transaction Report

Form 4
Period: 2025-08-06
Royalty Pharma plcRPRX
Legorreta Pablo G.
DirectorCEO, Chairman of the Board
Transactions
  • Gift

    LP interests in RPI US Partners 2019, LP

    2025-08-08−60,000→ 692,701 total
    → Class A Ordinary Shares (600,000 underlying)
  • Award

    Class A Ordinary Shares

    2025-08-06+21,901→ 904,396 total
Holdings

  • Class A Ordinary Shares

    (indirect: By Son)
    10,000

  • LP interests in RPI US Partners 2019, LP

    (indirect: By Spouse)
    Exercise: $0.00→ Class A Ordinary Shares (1,470,140 underlying)
    147,014

  • Class A Ordinary Shares

    (indirect: By Trust)
    41,306

  • Class A Ordinary Shares

    (indirect: By Tata MC 35 Ltd.)
    292,190

  • Class A Ordinary Shares

    (indirect: By Trust)
    600,000

  • LP interests in RPI US Partners 2019, LP

    (indirect: By LLC)
    Exercise: $0.00→ Class A Ordinary Shares (37,074,880 underlying)
    3,707,488

  • Class A Ordinary Shares

    (indirect: By Spouse)
    6,930

  • Class A Ordinary Shares

    (indirect: By LLC)
    460,139

  • Class A Ordinary Shares

    (indirect: By IRRA)
    123,310

  • Class A Ordinary Shares

    (indirect: By Trust)
    1,040,410

  • LP interests in RPI US Partners 2019, LP

    (indirect: By LLC)
    Exercise: $0.00→ Class A Ordinary Shares (18,323,630 underlying)
    1,832,363

  • Class A Ordinary Shares

    (indirect: By Daughter)
    10,000

  • Class A Ordinary Shares

    (indirect: By IRA)
    118,500

  • Class A Ordinary Shares

    (indirect: By Trust)
    901,590
Footnotes (3)
  • [F1]Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.
  • [F2]No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Amended and Restated Exchange Agreement. No additional value will be paid by the Reporting Person in connection with an exchange.
  • [F3]Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

Documents

1 file

Issuer

Royalty Pharma plc

CIK 0001802768

→
Entity typeother

Related Parties

1
  • filerCIK 0001507678

Filing Metadata

Form type
4
Filed
Aug 7, 8:00 PM ET
Accepted
Aug 8, 5:00 PM ET
Size
19.9 KB
View on SEC.gov